# US 2003/0206983 A1 · Antithrombotic agents

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0206983 A1
- Document ID: US20030206983A1
- Status: Published application
- Kind: A1
- Application number: 10/442,908
- Filed: 2003-05-20
- Published: 2003-11-06
- Earliest claimed: 1998-04-24
- Assignees: Provexis Limited
- Inventors: Asim Kanti Dutta-Roy
- Web page: https://patentgrep.com/patent/US20030206983A1

## CPC

- A61K 36/81: Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A23L 7/126: Snacks or the like obtained by binding, shaping or compacting together cereal grains or cereal pieces, e.g. cereal bars
- A23L 33/105: Plant extracts, their artificial duplicates or their derivatives
- A61K 35/20: Milk; Whey; Colostrum
- A61K 36/00: Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines {(antigens from pollen A61K39/36)}
- A61K 36/42: Cucurbitaceae (Cucumber family)
- A61K 36/73: Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K 36/752: Citrus, e.g. lime, orange or lemon
- A61K 36/899: Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
- A61K 36/8998: Hordeum (barley)
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Methods of prophylaxis or treatment of a disease state initiated by or characterized by platelet aggregation, that employ a fruit extract or active fraction thereof, are disclosed. In one embodiment, the fruit extract or active fraction thereof, is obtained from the fruit of plants of the families Solanaceae, Rutaceae, Cucurbitaceae, Rosaceae, Musaceae, Anacardiaceae, Bromeliaceae, Vitaceae, Arecaceae, Ericaceae and Lauraceae. Pharmaceutical compositions comprising a fruit extract or active fraction thereof having platelet aggregation inhibitory activity are also disclosed.

## Claims

### Claim 1

A method for the treatment of a condition or disorder mediated by platelet aggregation, the method comprising administering to a patient in need of such treatment, a therapeutically effective amount of a fruit extract having platelet aggregation inhibiting activity, and wherein the fruit extract is obtained from a fruit of the plant family Solanaceae, by a process comprising the steps of homogenizing the flesh of the fruit to form a homogenate and removing solids therefrom.

### Claim 2 (depends on 1)

A method according to claim 1, wherein the fruit is a tomato.

### Claim 3 (depends on 1)

A method according to claim 1, wherein the fruit extract is an aqueous extract.

### Claim 4 (depends on 2)

A method according to claim 2, wherein the tomato is peeled prior to the step of homogenizing.

### Claim 5 (depends on 1)

A method according to claim 1, wherein the fruit extract is in the form of a concentrate or a dehydrate.

### Claim 6 (depends on 5)

A method according to claim 5, wherein the extract is in the form of a concentrate which is at least 2-fold concentrated.

### Claim 7 (depends on 5)

A method according to claim 5, wherein the extract has been dehydrated to give a dry extract.

### Claim 8 (depends on 7)

A method according to claim 7, wherein the dry extract is in the form of a solid or semisolid dosage form.

### Claim 9 (depends on 8)

A method according to claim 8, wherein the extract is contained within a capsule shell.

### Claim 10 (depends on 1)

A method according to claim 1, wherein the extract contains a substantially heat stable, colorless or straw-colored, water soluble compound or compounds having a molecular weight of less than 1000.

### Claim 11 (depends on 1)

A method according to claim 1, wherein the condition or disorder is selected from the group consisting of myocardial infarction, stroke, cardiovascular disease, and disease states associated with platelet hyperactivity.

### Claim 12 (depends on 1)

A method according to claim 1, wherein the extract is in the form of an active fraction of the fruit capable of passing through an ultrafiltration filter having a molecular weight cut-off of 1000 and containing a substantially heat stable, colorless or straw-colored, water soluble compound or compounds having a molecular weight of less than 1000.

### Claim 13 (depends on 12)

A method according to claim 12, wherein the active fraction of the fruit:
(a) contains one or more nucleosides having platelet aggregation inhibiting activity; and
(b) exhibits an 1HNMR spectrum substantially as shown in FIG. 6.

### Claim 14 (depends on 12)

A method according to claim 12, wherein the active fraction of the fruit:
(a) contains one or more nucleosides having platelet aggregation inhibiting activity; and
(b) has a mass spectrum as shown in FIG. 7, when subjected to MALDI-TOF mass spectrometry.
